# A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer

> **NCT02454010** · PHASE1 · COMPLETED · sponsor: **Fujifilm Pharmaceuticals U.S.A., Inc.** · enrollment: 73 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **BIOLOGICAL:** FF21101

## Key facts

- **NCT ID:** NCT02454010
- **Lead sponsor:** Fujifilm Pharmaceuticals U.S.A., Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2021-10
- **Final completion:** 2021-10
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2025-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02454010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02454010, "A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02454010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*